Christos Fountzilas

22PUBLICATIONS
163CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersSolid tumoursChemotherapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (22)

|Mar 07, 2026
TP53 mutation is associated with improved disease control in patients with advanced RAS wild-type colorectal adenocarcinoma treated with cetuximab and pembrolizumab.

Christos Fountzilas, Spencer Rosario, Agnieszka K Witkiewicz

|Feb 11, 2026
Phase 1 open-label study of ASP9801, an oncolytic virus, in patients with advanced or metastatic solid tumors.

John L Villano, Jason J Luke, Ricklie Julian

|Feb 11, 2026
Development and Validation of a Computational Histology Artificial Intelligence-Powered Predictive Biomarker for Selection of Chemotherapy in Advanced Pancreatic Cancer.

Andrew E Hendifar, Viswesh Krishna, Vrishab Krishna

|Jan 12, 2026
Tucatinib plus trastuzumab for chemotherapy-refractory, HER2 + , RAS wild-type metastatic colorectal cancer (MOUNTAINEER): final analysis.

John H Strickler, Andrea Cercek, Salvatore Siena

|Nov 24, 2025
A Sequential Triple-Drug Strategy for Selective Targeting of p53-Mutant Cancers.

Mohammed M Alruwaili, Yanqi Guo, Justin Zonneville

|Nov 04, 2025
TRYBECA-1: A Randomized Phase III Study of Eryaspase Combined With Chemotherapy Versus Chemotherapy as Second-Line Treatment in Patients With Advanced Pancreatic Adenocarcinoma.

Pascal Hammel, Jean-Philippe Metges, Teresa Macarulla Mercade

Pageof 4

Frequent Collaborators

3 joint publications

Andrei V Bakin

2 joint publications

Eric Van Cutsem

2 joint publications

Teresa Macarulla Mercade

2 joint publications

Justin Zonneville